Dr Michael Huo speaks at an EHA 2010 press conference about a phase III prospective study comparing the dabigatran etexilate 220mg with enoxaparin 40mg as treatments to prevent venous thromboembolism (VTE) after total hip replacement surgery. The study showed dabigatran etexilate was as effective as enoxaparin but importantly also reduced the number of blood clots and deaths from blood clots.